Breckenridge Pharmaceutical, Inc. recalls
Breckenridge Pharmaceutical, Inc. is named on 15 recalls in Recall Relay's records since November 2023, from FDA (23 recalled products: FDA lists each product as its own recall); the most recent was June 4, 2026.
All 23 recalled products, newest first.
-
Class IIofficial
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
-
Class IIofficial
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
-
Class IIofficial
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules USPCGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
-
Class IIofficial
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesCGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
-
Class IIofficial
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesCGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
-
Class IIofficial
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.
-
Class IIofficial
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesCGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.
-
Class IIofficial
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
-
Class IIofficial
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit
-
Class IIofficial
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
-
Class IIofficial
Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release Capsules USPCGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
-
Class IIofficial
Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release Capsules USPCGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
-
Class IIofficial
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.
-
Class IIofficial
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
-
Class IIofficial
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
-
Class IIofficial
Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
-
Class IIofficial
Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
-
Class IIofficial
Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
-
Class IIofficial
Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
-
Class IIofficial
Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
-
Class IIofficial
Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
-
Class IIofficial
Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
-
Class IIofficial
Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release CapsulesCGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
This page groups recalls by the company name the agency printed, so it can include different companies with similar names, and a recall may name a store or distributor rather than the maker. It counts the recalls in Recall Relay's records, not a company's whole history; an FDA recall that lists several products counts once. Open a recall to see its details and the agency's official notice, which is always the final word. Recall Relay isn't affiliated with any agency or with the companies named here.
Severity labels say where they come from: “official” is the agency's own class, “advisory” is based on the agency's safety warning, and “est. risk” is Recall Relay's estimate from the hazard description, not an agency classification.
Hear about the next one
Recall Relay can email you when a new recall mentions Breckenridge Pharmaceutical, Inc. or any words you choose. Start with a free key (no card needed), then set up alerts on your account page.
Get recall alerts